Eli Lilly retatrutide Phase 3 data have drawn attention for the scale of weight loss reported across the TRIUMPH clinical trial program. In the supplied results, average weight loss reached 28.3% at 80 weeks in TRIUMPH-1, while a smaller extension group had a reported average reduction of 30.3% at 104 weeks.
Additional findings from TRIUMPH-2 and TRIUMPH-3 broadened the evidence base, including results in people with type 2 diabetes. However, these figures need context: different study populations, follow-up periods and analysis methods can affect how trial results should be interpreted.
Retatrutide remains investigational and is not approved. The findings describe outcomes reported in clinical research, not guaranteed results for individuals or an available treatment recommendation.
What Is Retatrutide?
Retatrutide is an investigational medicine being developed by Eli Lilly. Lilly describes it as a triple agonist, distinguishing its development approach from medicines that target fewer receptor pathways.
The Phase 3 TRIUMPH program evaluates retatrutide in larger clinical studies. These trials help establish whether the findings are sufficiently consistent, clinically meaningful and supported by an acceptable safety profile to warrant regulatory consideration.
For readers searching for Eli Lilly retatrutide Phase 3 data, the central question is not simply how much weight participants lost. It is also how the studies were designed, which participants were enrolled, how long they were followed and what remains unresolved.
Retatrutide Phase 3 Results at a Glance
The supplied references describe results from three studies and an extension of TRIUMPH-1:
- TRIUMPH-1: A 2,339-participant trial with reported average weight loss of 28.3% in the 12 mg group, 25.9% in the 9 mg group and 19.0% in the 4 mg group at 80 weeks.
- TRIUMPH-1 extension: A 532-person extension with reported average weight loss of 30.3% at 104 weeks.
- TRIUMPH-2: A 1,152-participant study in people with type 2 diabetes, reporting 20.8% average weight loss in the 12 mg group versus 4.0% with placebo, alongside an A1C reduction of 1.6%.
- TRIUMPH-3: A 1,949-participant study reporting 22.6% average weight loss in the 12 mg group versus 3.2% with placebo.
The milligram amounts identify study treatment groups. They are not dosing instructions, and investigational trial regimens should not be interpreted as guidance for personal use.
TRIUMPH-1: What the 80-Week Results Showed
TRIUMPH-1 results were reported on 21 May 2026. The study included 2,339 participants and provided the highest reported average weight-loss figure among the main trial results summarized here.
Reported Weight Loss Across Study Groups
At 80 weeks, the reported average reductions were 28.3%, 25.9% and 19.0% in the 12 mg, 9 mg and 4 mg groups, respectively. These findings showed a numerical pattern of greater average weight reduction in the higher-dose study groups.
Nevertheless, averages do not describe every participant. Some people may have experienced greater reductions, while others may have experienced smaller reductions or discontinued treatment. The supplied summary does not provide the full distribution of individual outcomes.
It also does not include a TRIUMPH-1 placebo figure. Consequently, the active-treatment percentages should not be presented here as placebo-adjusted results.
The 104-Week Extension
A 532-person extension reported average weight loss of 30.3% at 104 weeks. This longer follow-up is relevant because it adds information beyond the main 80-week assessment.
However, the extension involved a smaller group than the original trial. Readers should not assume that its result represents all 2,339 original participants. Understanding extension eligibility, participant retention and the analysis population would be important when evaluating the longer-term finding.
TRIUMPH-2: Results in Type 2 Diabetes
TRIUMPH-2 results were announced on 23 July 2026. The study enrolled 1,152 participants with type 2 diabetes.
The reported average weight reduction was 20.8% in the 12 mg group, compared with 4.0% in the placebo group. That represents a numerical difference of 16.8 percentage points between the reported averages.
The supplied results also reported an A1C reduction of 1.6%. A1C is a measure used to assess blood glucose levels over time, making it an important outcome in a diabetes study.
These findings provide evidence about weight and glycemic outcomes within the trial population. They do not establish that every person with type 2 diabetes would experience the same changes, nor do they independently establish effects on complications or other long-term health outcomes.
TRIUMPH-3: Another Placebo-Controlled Result
TRIUMPH-3 results were also announced on 23 July 2026. The study included 1,949 participants.
Average weight loss was reported as 22.6% in the 12 mg group versus 3.2% with placebo. The numerical difference between those averages was 19.4 percentage points.
This result adds another large study to the retatrutide Phase 3 evidence base. However, the supplied reference summary does not detail the population characteristics, study duration or complete statistical analysis for TRIUMPH-3.
Those omissions matter when comparing it with TRIUMPH-1 or TRIUMPH-2. A lower or higher percentage across separate studies does not, by itself, explain differences in treatment performance.
How to Interpret the Retatrutide Trial Data
Average Results Are Not Individual Predictions
A trial average summarizes outcomes across an analysis group. It is not a forecast for any particular person. Baseline characteristics, treatment discontinuation and individual responses can all influence the range of results behind a headline percentage.
Separate Trials Are Not Head-to-Head Comparisons
The TRIUMPH studies provide multiple pieces of evidence, but they should not be treated as interchangeable. TRIUMPH-2 specifically enrolled people with type 2 diabetes, while the supplied summaries provide different levels of detail for the other studies.
Likewise, these figures do not establish superiority over another medicine. That conclusion would require suitable comparative evidence rather than a comparison of headline results from unrelated trials.
Full Analyses Add Essential Context
Detailed reports are needed to assess how missing data, discontinuations and statistical assumptions were handled. Those details help distinguish the reported treatment effect under a particular analysis from what might occur across broader clinical practice.
What Do the References Say About Safety?
The supplied reference material focuses on efficacy results and does not provide detailed adverse-event rates. It therefore does not support specific claims about common side effects, serious adverse events or treatment discontinuation rates.
Large reported weight reductions should not be interpreted as proof of safety. A complete assessment requires efficacy and safety findings together, including tolerability, reasons for stopping treatment and any risks identified during follow-up.
Is Retatrutide Approved?
Retatrutide is not approved. According to the supplied material, Lilly plans an FDA biologics license application submission in the first quarter of 2027.
A planned submission is not an approval decision. Regulatory review would assess the submitted evidence, and neither the filing plan nor positive trial announcements guarantee authorization or establish an availability date.
The Bottom Line
The Eli Lilly retatrutide Phase 3 data show substantial reported average weight reductions across TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3. The 104-week extension adds a longer-term observation, while TRIUMPH-2 also reports an A1C reduction in participants with type 2 diabetes.
The key distinction is between promising research findings and an approved treatment. Retatrutide remains investigational, and fuller trial reports and regulatory evaluation are essential to understanding its benefit-risk profile.
